These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2364642)

  • 61. In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers.
    Asmus MJ; Milavetz G; Tice AL; Teresi ME
    Pharmacotherapy; 2001 May; 21(5):534-9. PubMed ID: 11349742
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measuring nebulizer output. Aerosol production vs gravimetric analysis.
    Tandon R; McPeck M; Smaldone GC
    Chest; 1997 May; 111(5):1361-5. PubMed ID: 9149595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Best practice in the provision of nebuliser therapy.
    Kelly C; Lynes D
    Nurs Stand; 2011 Apr 6-12; 25(31):50-6; quiz 58. PubMed ID: 21560711
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transitional concentration of antibacterial agent to the maxillary sinus via a nebuliser.
    Kondo H; Suzuki K; Takagi I; Miyamoto N; Baba S; Kobayashi T; Yokota A; Tanaka I; Sugiyama K
    Acta Otolaryngol Suppl; 1996; 525():64-7. PubMed ID: 8908273
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differences in aerosol output and airways responsiveness between the DeVilbiss 40 and 45 hand held nebulisers.
    Hartley-Sharpe CJ; Booth H; Johns DP; Walters EH
    Thorax; 1995 Jun; 50(6):635-8. PubMed ID: 7638805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial.
    Dentice RL; Elkins MR; Dwyer GM; Bye PTP
    BMC Pulm Med; 2018 Jan; 18(1):3. PubMed ID: 29310638
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Establishing standardised methods for comparing aqueous droplet inhalers.
    Berg E; Svensson JO
    Pharmeur Sci Notes; 2006 Dec; 2006(2):9-15. PubMed ID: 17691209
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Performance Comparisons of Jet and Mesh Nebulizers Using Different Interfaces in Simulated Spontaneously Breathing Adults and Children.
    Ari A; de Andrade AD; Sheard M; AlHamad B; Fink JB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):281-9. PubMed ID: 25493535
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dilution of nebulised aerosols by air entrainment in children.
    Collis GG; Cole CH; Le Souëf PN
    Lancet; 1990 Aug; 336(8711):341-3. PubMed ID: 1975336
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy.
    Teale C; Morrison JF; Jones PC; Muers MF
    Respir Med; 1991 Jul; 85(4):281-4. PubMed ID: 1835110
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.
    Thomas SH; O'Doherty MJ; Graham A; Page CJ; Blower P; Geddes DM; Nunan TO
    Thorax; 1991 Oct; 46(10):717-21. PubMed ID: 1750018
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nebulised gentamicin-suitable for childhood bronchiectasis.
    Twiss J; Byrnes C; Johnson R; Holland D
    Int J Pharm; 2005 May; 295(1-2):113-9. PubMed ID: 15847996
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nebuliser therapy: what nurses and patients need to know.
    Dodd ME
    Nurs Stand; 1996 Apr; 10(31):39-42. PubMed ID: 8703784
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design characteristics for drug nebulizers.
    Dennis JH; Hendrick DJ
    J Med Eng Technol; 1992; 16(2):63-8. PubMed ID: 1404307
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inaccurate calculation of drug output from nebulisers.
    O'Callaghan C; Clarke AR; Milner AD
    Eur J Pediatr; 1989 Feb; 148(5):473-4. PubMed ID: 2493380
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improvement of nebulised antibiotic delivery in cystic fibrosis.
    Wilson D; Burniston M; Moya E; Parkin A; Smye S; Robinson P; Littlewood J
    Arch Dis Child; 1999 Apr; 80(4):348-52. PubMed ID: 10086942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chitosan-coated antifungal formulations for nebulisation.
    Albasarah YY; Somavarapu S; Stapleton P; Taylor KM
    J Pharm Pharmacol; 2010 Jul; 62(7):821-8. PubMed ID: 20636869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.
    Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A
    Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Daily Observations of Nebuliser Use and Technique (DONUT) in children with cystic fibrosis.
    Bos AC; Tiddens HA; Tong Minh K; Heeres I; Overweel-Uijterlinde JL; Kok AE; Andrinopoulou ER; Janssens HM
    J Cyst Fibros; 2016 Sep; 15(5):645-51. PubMed ID: 27052127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.